# Novartis Pharma S.A.S. - Centre de Biotechnologie – FDA Inspection, Sep 12, 2017

Source: https://www.keypedia.com/records/fda_inspections/novartis-pharma-sas-centre-de-biotechnologie/8615aa30-3785-4cab-af8d-bbcb1a2be973
Source feed: FDA_Inspections

> FDA inspection 1026805 of Novartis Pharma S.A.S. - Centre de Biotechnologie, September 12, 2017. Classification: Voluntary Action Indicated (VAI). Form 483 issued. 3 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1026805
- Company Name: Novartis Pharma S.A.S. - Centre de Biotechnologie
- Inspection Date: 2017-09-12
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1173120 - 2020-11-19
- FDA Inspection 878418 - 2014-03-18
- FDA Inspection 787415 - 2012-01-31

## Related Officers

- [FDA Associated Person](https://www.keypedia.com/people/carla-j-lundi/a10ed698-54fe-4635-a766-8c31f501dfb2)
- [Company Rep](https://www.keypedia.com/people/xiaoping-guan/191018c9-9f60-4db0-a9eb-48314b53e515)

Company: https://www.keypedia.com/companies/novartis-pharma-sas-centre-de-biotechnologie/af3b3928-8e26-49ec-b7d4-865a757d3a53

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c